Author: RZNOMICS INC.

Rznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to ‘RZ-001’ for Hepatocellular Carcinoma

May 8, 2026
Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile

April 20, 2026

Rznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to ‘RZ-001’ for Hepatocellular Carcinoma